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Abstract
Major depression is nearly twice as prevalent in women compared to men. In bipolar disorder, depressive episodes have
been reported to be more common amongst female patients. Furthermore, periods of depression often correlate with
periods of hormonal fluctuations. A link between hormone signaling and these mood disorders has, therefore, been
suggested to exist in many studies. Estrogen, one of the primary female sex hormones, mediates its effect mostly by binding
to estrogen receptors (ERs). Nuclear ERs function as transcription factors and regulate gene transcription by binding to
specific DNA sequences. A nucleotide change in the binding sequence might alter the binding efficiency, which could affect
transcription levels of nearby genes. In order to investigate if variation in ER DNA-binding sequences may be involved in
mood disorders, we conducted a genome-wide study of ER DNA-binding in patients diagnosed with major depression or
bipolar disorder. Association studies were performed within each gender separately and the results were corrected for
multiple testing by the Bonferroni method. In the female bipolar disorder material a significant association result was found
for rs6023059 (corrected p-value=0.023; odds ratio (OR) 0.681, 95% confidence interval (CI) 0.570–0.814), a single nucleotide
polymorphism (SNP) placed downstream of the gene coding for transglutaminase 2 (TGM2). Thus, females with a specific
genotype at this SNP may be more vulnerable to fluctuating estrogen levels, which may then act as a triggering factor for
bipolar disorder.
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Introduction
Women are diagnosed with mood disorders much more
frequently than men. As a consequence, the reported lifetime
prevalence rate in women for developing major depression is
nearly twice as high compared to men. In the Netherlands Mental
Health Survey and Incidence Study (NEMESIS) and the
American National Comorbidity Survey (NCS), two large cross-
sectional population studies with comparable designs, for example,
the female to male ratio was 1.8 and 1.65, respectively [1–4]. Both
studies used the Diagnostic and Statistical Manual of Mental
disorders, 3
rd edition, revised (DSM-III-R) as diagnostic criteria
and the Composite International Diagnostic Interview (CIDI) as
the psychiatric interview. NEMESIS reported a life-time preva-
lence for major depression in women of 24.5%, which is roughly
equivalent with the 21% reported for women in the NCS study.
For males, the life-time prevalence was reported to be 13.6% in
the NEMESIS study and 12.7% in the NCS study. Whether the
reported gender difference in prevalence is due to biological
differences (e.g. differences in endocrine levels) or other factors
(e.g. social status discrimination, social stress or gender differences
when it comes to reporting symptoms) has for long been a matter
of debate [3,5,6]. For bipolar disorder (also known as manic
depression), the prevalence rate is equal in women and men (1%)
[7–9]. Biological differences in the etiology may still exist, since it
has been reported that depressive episodes may be more common
in female compared to male bipolar patients [8,10]. Moreover,
periods of hormonal fluctuations (e.g. premenstrually, postpartum
and postmenopausally) have in numerous studies been reported to
be associated with increased risk of affective dysregulation and
vulnerability to develop depression [11–14]. Postpartum depres-
sion occurs in up to 10–20% of mothers in the year following
delivery [15]. For women with a previous diagnosis of a mood
disorder, the risk is even higher with reported rates of
approximately 20–30% for women with major depression and as
high as 25–52% for women diagnosed with bipolar disorder
[15,16]. Postmenopausal women, with reduced estrogen levels,
benefit less from antidepressant treatments compared to premen-
opausal women [17].
In addition to regulating reproduction and modulating sexual
behavior, estrogen, one of the primary female sex hormones,
affects several other systems in the body such as the cardiovascular,
musculoskeletal, immune and central nervous systems [18,19].
Estrogen mediates its effects mostly by binding to estrogen
receptors (ERs). There are two different types of ERs: one is a
member of the nuclear hormone family of intracellular receptors
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study focuses on the role of the nuclear hormone receptor, a DNA
binding transcription factor involved in gene regulation and
expression. Two forms of this type of the receptor occur: ERa and
ERb. In order to bind to DNA, this receptor forms either
homodimers (a/a or b/b) or heterodimers (a/b).
The DNA binding of ERs is either direct, where the dimer itself
binds to specific DNA sequences (so called Estrogen Response
Elements, EREs) or through a tethered pathway where the ER
dimer binds to other transcription factors (like AP-1 and SP-1)
which bind to DNA sequences lacking EREs. In either case, ER
binding has an effect on gene transcription. The derived minimal
consensus ERE sequence is a 13 base pair palindromic inverted
repeat: 59-GGTCAnnnTGACC-39, where n is any nucleotide
[20–22]. Many functional ERE-sequences vary from the consensus
by one or more nucleotides. However, it has also been shown that
a single nucleotide change may completely disrupt the ER-binding
ability [20].
Since ERa and ERb function as transcription factors by binding
to specific DNA sequences and regulate gene transcription, a
nucleotide change in the ER-binding sequence could possibly
affect the binding and lead to abnormal function. This might alter
transcription levels of nearby genes, which could have an effect on
the cell function and could be part of a disease mechanism. The
aim of this study was therefore to carry out association studies
between ER DNA-binding sequence polymorphisms in women or
men with bipolar disorder or major depression compared to
healthy controls.
Several studies have investigated a possible involvement of ERs
in the etiology of psychiatric disorders. To our knowledge, all of
them have had a different approach than employed in this study,
investigating the genomic areas of the ERa and ERb genes
themselves. Two studies of possible involvement of the ERa- and
ERb-genes in bipolar disorder could not find any association with
disease [23,24]. However, Weickert et al [25] reported that
differences in the ERa gene and its mRNA expression contributed
to risk for developing schizophrenia, and another study found that
persons committing suicide had decreased levels of ERb mRNA
[26].
To our knowledge, no one has so far conducted a systematic
and genome-wide study of differences in ER-DNA binding
sequences in mood disorders. We therefore designed a study to
search for such differences in patients diagnosed with major
depression or bipolar disorder. Due to above-mentioned differ-
ences in the prevalence and etiology of mood disorders between
women and men, we decided to carry out analyses for each gender
separately. Correction for multiple testing was carried out using
the Bonferroni method.
Materials and Methods
Material
Study population. Genome-wide genotype data for patients
diagnosed with either bipolar disorder or major depression and
healthy controls were obtained from the Genetic Association
Information Network (GAIN). Genotype data for 964 cases (487
women and 477 men) diagnosed with bipolar disorder and 998
healthy controls (490 women and 508 men) as well as 1727 cases
(1200 women and 527 men) diagnosed with major depression and
1758 controls (1076 women and 682 men) were included in the
final data set for the association analyses.
The individuals included in the study on bipolar disorder come
from the National Institute of Mental Health Human Genetics
Initiative (NIMH GI; http://nimhgenetics.org/). Cases used
within our study are individuals with European Ancestry that
have been collected and characterized by the NIMH GI for
Bipolar Disorder Consortium (Bipolar consortium). The cases
were diagnosed with a standard best estimate final diagnosis
(BEFD) procedure and interviewed with the Diagnostic Interview
for Genetic Studies (DIGS). The control subjects, also of European
ancestry, were collected separately through a NIMH-supported
contract mechanism between Dr. Pablo Gejman and Knowledge
Networks, Inc. Individuals were excluded from the study after the
quality control analyses if they failed any of several quality metrics,
such as: low call rate, excessively high or low heterozygosity,
incompatibility between reported gender and genetically deter-
mined gender, or unexpected familial relationships [9].
For the major depression study, the cases came from the
Netherlands Study of Depression and Anxiety (NESDA; http//
www.nesda.nl), which is a longitudinal cohort study. Inclusion
criteria were a lifetime diagnosis of DSM-IV MDD as diagnosed
by the Composite International Diagnostic Interview psychiatric
interview, age 18–65 years, and self-reported western European
ancestry. The cases were recruited from mental health care
organizations, primary care, and community samples. The control
subjects were derived from the Netherlands Twin Register (NTR;
http://www.tweelingenregister.org), which has collected longitu-
dinal data from twins and their families since 1991. Individuals
that did not meet quality control criteria were removed from the
study. Such criteria could be: individuals with uncertain linkage
between genotype and phenotype, individuals with genomic
outliers, such as too high genome-wide homozygosity (,75%),
samples with contamination or individuals that either failed
genotyping or had had excessive missing genotype data (,25%)
[27].
Ethics Statement. Written informed consent had been
obtained by the original investigators from all participants in the
study. The study was conducted in accordance with data use
certification agreements between the Genetic Association
Information Network (GAIN) and the investigators.
Single Nucleotide Polymorphisms (SNPs) included in our
study. The bipolar disorder samples were genotyped by the
Broad Institute Center for Genotyping and Analysis (http://www.
broad.mit.edu/node/306) and has been described by Smith et al
[9]. The Affymetrix Genome-Wide Human SNP Array 6.0
platform was used for the genotyping. Briefly, the initial quality
control removed SNPs if the minor allele frequency was ,0.01,
the call rate was ,95%, if the SNP had a Hardy-Weinberg
Equilibrium p-value of ,1610
26 in the control sample, if there
were three or more Mendelian errors in HapMap trios included in
the run for quality control purposes, or if there was more than one
discrepancy among duplicate samples. Of the 729 454 SNPs that
passed the initial QC analyses in the bipolar disorder study,
724 067 SNPs were included in the dataset obtained through
dbGAP (database of Genotypes and Phenotypes). Study Accession
id for the bipolar study is phs000017.v3.p1.
The genotyping of the major depression sample was conducted
by Perlegen Sciences (Mountain View, CA, USA) and has been
described elsewhere [28]. The Perlegen GWAS platform used for
the analysis contained 599 156 SNPs. Briefly, the initial quality
control analyses removed SNPs with the following features: gross
mapping problem, $2 genotype disagreements in 40 duplicated
samples, $2 Mendelian inheritance errors in 38 complete trio
samples, minor allele frequency ,0.01 or .0.05 missing
genotypes in either cases or controls. A Hardy-Weinberg filter
was not used. A total of 435 291 SNPs survived the initial quality
control analyses and were included in the released data set (dbGaP
Accession Study phs000020.v2.p1).
ER DNA-Binding Variation in Mood Disorders
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Perl scripts were written for all data manipulation and PLINK,
a free, open-source whole genome association analysis toolset
(http://pngu.mgh.harvard.edu/,purcell/plink/), was used for
additional quality control steps, association analysis, and statistical
calculations.
SNPs located in ER binding regions were identified by two
approaches: a) the use of publicly available genome-wide
Chromatine Immuno Precipitation (ChIP) data on ERa and
ERb binding regions, and b) Estrogen Response Element (ERE)
sequence information. In order to have sufficient confidence in a
candidate polymorphism, we decided to include into the study 1)
those polymorphisms that were found in regions consistently
implicated by functional studies (whether or not a predicted ERE
binding site was present) and 2) those polymorphisms that were
found to be located in in-silico predicted binding sites that were
validated by at least one functional study.
A) Identifying SNPs in ChIP-regions
Genome wide Chromatine Immuno Precipitation (ChIP) results
of ER DNA-binding were obtained from three sources: [29–31].
The three studies differed regarding ER-subtype studied, ChIP
method used and number of ER-binding sites identified. Carroll et
al studied the ERa by regular ChIP technique and found 3 655
binding sites, while Lin et al also studied the ERa but with a ChIP-
PET method and identified 1 234 binding sites. Zhao et al studied
the ERb with regular ChIP technique and identified 1 457
binding sites. In our study we included SNPs located within 343
regions where the three ChIP studies agreed with each other.
B) Identifying SNPs in ERE-sequences
After downloading IUPAC masked FASTA-files (Mar.
2006(hg18) SNP129) from the UCSC Genome Browser website
(http://genome.ucsc.edu/), we searched through the genome for
ERE-halfsite core sequences (GGTCA or TGACC) that contained
SNPs. We then sought additional support for this in-silico
prediction from the ChIP studies and included those ERE binding
site disrupting SNPs that were in regions supported by any of the
three ChIP-studies.
Identifying SNP genotypes
For interesting SNPs identified by the methods above but not
genotyped in the GAIN data, we tried to find other, genotyped
SNPs that were in high Linkage Disequilibrium (LD) (r
2.0.89).
HapMap linkage disequilibrium data (HapMap population CEU,
HapMap_rel23a_NCBI_Build 36) was downloaded (http://hap-
map.ncbi.nlm.nih.gov/), allowing us to identify markers in high
LD with SNPs selected for our study.
Data management and statistics prior to association
analyses
In addition to the quality control performed by the original
investigators of the two GAIN studies, we performed a few further
quality control steps and excluded SNPs with missing genotypes
.0.05, minor allele frequencies ,0.01, and Hardy-Weinberg
Equilibrium (HWE) p-value of ,0.001 in the controls. Individuals
were excluded from the study if the missing genotype rate/person
was .0.1.
Association studies
A two-tailed Fisher’s exact test was used to study associations
between the case and control groups. Association analyses were
performed separately in each disease and for each gender. Since
two independent populations (female or male) and two indepen-
dent datasets (major depression or bipolar disorder) were used,
Bonferroni correction was appropriate, correcting for a total
number of four independent hypotheses and 225 SNPs. Each p-
value was thus multiplied by 900 (2626225) to give us the
Bonferroni-corrected p-values.
Results
SNPs included in our study
A flowchart of the selection and inclusion process of the SNPs
included in our study is shown in Figure 1. A total of 351 SNPs
were identified to be located within regions where the three
experimental ChIP-studies overlapped. Of these, 117 were
genotyped in the GAIN bipolar disorder study and 98 were
genotyped in the GAIN major depression study. Additionally, 95
SNPs were found to be placed in ERE-halfsite sequences within
any of the three ChIP-studies, and they were thus also included in
our study. 25 of these SNPs had been genotyped in the bipolar
disorder study and 22 of them had been genotyped in the major
depression study.
For the selected SNPs not genotyped by GAIN we tried to find
another SNP in high LD (r
2=0.89) with the SNP of interest that
was included in the GAIN study.138 such SNPs were added to the
bipolar disorder study and 155 high LD SNPs were included in the
major depression sample. In total we thus had 280 SNPs for the
bipolar disorder study and 275 SNPs for the major depression
study that were either identified in all three ChIP-studies or placed
in a ERE-sequence within any of the three ChIP-studies. These
SNPs had either been genotyped in the GAIN material or were in
high LD with a SNP included in the GAIN material.
After quality control, the final datasets for the association
analyses included 225 SNPs in the female bipolar disorder sample
and 224 in the male sample. The major depression study
contained 218 SNPs in the male analysis and 217 SNPs in the
female analysis.
Association analyses
The complete association results can be seen in Tables S1, S2,
S3, and S4. Results for the top-ranking SNPs in each study are
summarized in Table 1. After correction for multiple testing,
rs6023059 showed statistically significant association with disease
(corrected p-value=0.023; odds ratio (OR) 0.681, 95% confidence
interval (CI) 0.570–0.814) in the female bipolar disorder material.
In the male bipolar disorder sample as well as in the major
depression samples the association results for this SNP were non-
significant. This SNP is in high LD (r
2=0.89) with rs909859, a
SNP located in a region identified by all three ChIP-studies. Both
SNPs are placed in the downstream genetic region of two genes,
see Table 2 describing the genomic locations of the SNPs
identified in the association analyses. The first gene codes for
Transglutaminase 2 (TGM2) and is located on the genomic
reverse strand. The second gene is called RPRD 1B, located on
the forward strand. The TGM2 gene has previously shown to be
implicated in neurodegenerative diseases [32] and has been shown
to be regulated by estrogen in numerous studies, see Table 3 for
the function of the identified SNPs and their estrogen regulations
[33–35].
None of the other SNPs reached significance after correcting for
multiple testing, but several of the top results (including the
second-ranking SNP in the female bipolar disorder material) were
obtained in interesting genetic regions previously implicated in the
pathogenesis of psychiatric disease. Two of the identified SNPs,
ER DNA-Binding Variation in Mood Disorders
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Table 1. Association study results.
disease gender rs-number alleles
1
MAF
2
(cases)
MAF
2
(controls) p-value
corrected
p-value
3 OR
4 L95
5 U95
6
bipolar disorder female rs6023059 C,T 0.4251 0.5204 0.00002509 0.023 0.681 0.570 0.814
bipolar disorder female rs867286 A,G 0.2922 0.3722 0.0001777 0.160 0.696 0.576 0.842
bipolar disorder male rs6517590 A,G 0.4906 0.4270 0.005008 .1 1.292 1.082 1.543
major depression female rs7217437 C,T 0.4783 0.4345 0.00318 .1 1.193 1.062 1.342
major depression male rs16848941 C,T 0.1613 0.1081 0.000155 0.140 1.587 1.251 2.012
1minor allele,major allele.
2minor allele frequency.
3p-value corrected with Bonferroni correction.
4estimated odds ratio for the minor allele.
5lower bound of 95% confidence interval for odds ratio.
6upper bound of 95% confidence interval for odds ratio.
doi:10.1371/journal.pone.0032304.t001
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(PITPNC1 and PRKCE respectively) involved in the inositol
pathway. In numerous studies this pathway has been linked to
bipolar disorder. Furthermore, lithium, the primary therapeutic
treatment for bipolar disorder, works regulatory on this pathway
[36–38]. The marker rs6517590 is placed in intron 21 in the gene
coding for Down syndrome cell adhesion molecule (DSCAM),
which is highly important for neural development and contributes
to the disease mechanisms in Down syndrome.
Discussion
To our knowledge, this is the first study to examine the possible
involvement of differences in ER-DNA binding sequences in mood
disorders. After correcting for multiple testing, a significant
association was found for rs6023059 (corrected p-value=0.023;
OR 0.681, 95% CI 0.570–0.814) in the female bipolar disorder
material. Thus, our results suggest that this variation in ER-
binding sequence may influence risk to become affected by bipolar
disorder in women.
Studies reporting a gender difference in the phenotype of
depression suggest that these differences might be coupled to
differences in estrogen levels and hormonal fluctuations (for review
see [14]). Several studies have shown that periods of depression
often correlate with hormonal fluctuations in women with bipolar
disorder or major depression [10–16]. Both these disorders are
highly heritable diseases with a complex genetic pattern and a
substantial polygenic component. In addition it has previously
been suggested that there is also a gender difference in the genetic
component of mood disorders [39], a hypothesis our results
support.
Genome-wide association studies offer a powerful tool to study
genetically complex diseases. The first-pass analysis usually
includes all markers after quality control and demands significant
results to survive genome-wide correction for multiple testing.
However, this correction may be over-conservative. While, given
Table 2. Genomic information for the top associated SNPs.
disease gender rs-number chr
1
position
(bp)
2 nearby gene
SNP position relative
to nearby gene
bipolar disorder female rs6023059 20 36171185 TGM2: transglutaminase 2 and
RPRD 1B
56 kb downstream of TGM2 and
17 kb downstream of RPRD1B
bipolar disorder female rs867286 2 45835534 PRKCE: protein kinase C, epsilon intron 1
bipolar disorder male rs6517590 21 40618105 DSCAM: Down syndrome cell
adhesion molecule
intron 21
major depression female rs7217437 17 62894224 PITPNC1: phosphatidylinositol
transfer protein, cytoplasmic 1
intron 1
major depression male rs16848941 2 164384159 GRB14: Growth factor receptor
binding protein 14
673 kb downstream of GRB14
1chromosome.
2base pair.
doi:10.1371/journal.pone.0032304.t002
Table 3. Function of genes proximal to the SNPs identified in the association studies.
disease gender rs-number nearby gene function
estradiol
regulation
previously associated
with mood disorders
bipolar disorder female rs6023059 TGM2:
transglutaminase
2
Calcium dependent enzyme that
catalyzes crosslinking of proteins.
Involved in cytoskeleton
stabilization, apoptosis, cell
differentiation, cell adhesion and
GTP-hydrolysing activity.
down regulation/
decreased activity
yes
bipolar disorder female rs6023059 RPRD1B Involved in regulation of nuclear
pre-mRNA domain containing.
unknown no
bipolar disorder female rs867286 PRKCE: protein
kinase C, epsilon
Involved in neuron channel
activation and apoptosis. Protein
activated by calcium and DAG.
down and up
regulation depending
on the stimulation
context within the cell
yes
bipolar disorder male rs6517590 DSCAM: Down
syndrome cell
adhesion molecule
Involved in Down syndrome,
cell adhesion and neuronal
development.
unknown yes
major depression female rs7217437 PITPNC1:
phosphatidylinositol
transfer protein
Cytoplasmic protein that transfers
phosphatidylinositol from one
membrane compartment to another.
up regulation/
increased activity
yes
major depression male rs16848941 GRB14 Adaptor protein that interacts with
tyrosin-kinases.
down regulation/
decreased activity
no
doi:10.1371/journal.pone.0032304.t003
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association results may thus be strong enough to overcome the
multiple testing problem when studying the entire dataset, there
may be other, more focused hypotheses that can be tested in the
same data. In this way, the multiple-testing problem can be
overcome to some extent by a smaller number of SNPs tested
within such hypothesis-driven approaches. Genes with a modest
influence on disease risk may be identified. Needless to say, there
are an infinite number of such possible hypotheses, and replication
in independent datasets remains crucial before definite conclusions
can be made.
After correction for multiple testing, a significant association
result was found for rs6023059 in the female bipolar disorder
material. This SNP is placed in the genomic interval between the
genes RPRD1B and TGM2. TGM2 is a ubiquitously expressed,
highly regulated multifunctional protein. When calcium-bound,
this enzyme has a cross-linking activity forming e(c-glutamyl)lysine
bonds within or between various proteins. TGM2 has been shown
to be important for several different cellular processes such as
cytoskeleton stabilization, apoptosis, cell differentiation, cell
adhesion, and even GTP-hydrolysing activity. TGM2 activity is
also well known to be involved in celiac disease (CD), a chronic,
auto-immune mediated, small-intestinal disorder characterized by
inflammatory injury to the mucosa following ingestion of wheat
gluten [40]. TGM2-specific antibodies are almost exclusively
found in CD and are therefore used as a diagnostic indicator of
CD [41]. In addition, TGM2 has also been implicated in the
etiology of several neurological disorders such as Huntington’s
disease, Alzheimer’s disease (AD), Parkinson’s disease (PD) and
schizophrenia [32,40,42–45].
Apparently, some women are more vulnerable to normal
hormonal fluctuations (eg premenstrually, during the postpartum
period and perimenopausally) than others. In these women, a
drastic decrease in estrogen levels might increase the risk for
experiencing anxiety and depressive symptoms [46]. Reduced
levels of estrogen has been shown to increase the activity of the
TGM2 protein, something Assisi et al could see when studying
apoptosis mediated by TGM2 in the frog liver [33]. In concert
with this Fujita et al showed a distinct reduction of the activity of
the TGM2 enzyme after estrogen administration, something
which inhibited the apoptotic processes in the hippocampus
mediated by the TGM2 enzyme [35]. Increased apoptotic activity
in patients diagnosed with bipolar disorder compared to healthy
controls has been reported in numerous studies [47–50].
Moreover, it seems that one of the effects seen by lithium is
reduced neuronal apoptosis [51–53]. In addition, lithium has an
effect on intra cellular calcium homeostasis, which in many cases
have been shown to be impaired in bipolar patients [54–56].
Calcium is required for TGM2 to be able to adopt a catalytically
active conformation. Thus, a perturbed calcium homeostasis, as
seen in many bipolar patients, might result in an inappropriate
activation of the enzyme [32].
Numerous studies have shown that estrogen can exert an anti-
inflammatory effect in the brain. Several in vivo studies on
lipopolysaccaride (LPS) induced inflammation in microglia and
astrocytes have shown that estrogen administration reduces
microglia as well as astrocyte reactivities and down regulates the
release of nitric oxide (NO) and several pro-inflammatory
cytokines, such as tumor necrosis factor a (TNF-a) and IL-6
[57–60]. The NO synthesis in activated microglia has been shown
to correlate with an increase of the TGM2 protein expression.
Moreover, inhibition of the TGM2 enzyme can reduce the NO
secretion in a dose-dependent manner [61]. The TGM2 protein is
expressed throughout the body and most notably in the brain. One
may thus speculate that immunological reactivity against TGM2
in vulnerable persons may trigger an inflammatory response which
may cause damage to neurons [40].
The second top-SNP in the female bipolar material is placed in
intron 1 in a gene coding for protein kinase C epsilon (PRKCE).
This protein modulates neuronal calcium signaling by binding to
specific voltage-gated calcium channels expressed in the axons
[36,62,63]. Several studies have reported increased levels of basal
calcium levels in blood samples from patients with bipolar disorder
and it has been suggested that dysregulation of intracellular
calcium homeostasis may be involved in controlling mood states in
this disease [36]. Lithium, the primary therapeutic choice for
bipolar disorder, has been shown to decrease the levels of PRKCE,
a mechanism that could be involved in the therapeutic effect of this
drug [36,64].
In the male bipolar disorder study the best association result was
received for a SNP placed in intron 21 in the gene coding for Down
syndrome cell adhesion molecule (DSCAM) a gene known to be
involved in Down syndrom. DSCAM is important for neural
developmentand isinvolved in axon guidance, neural differentiation
and neural plasticity [65,66]. A possible involvement of the DSCAM
gene in bipolar disorder has previously been reported [65].
In the female major depression sample the top-SNP is placed in
intron 1 in the gene phosphatidylinositol transfer protein
(PITPNC1), a cytoplasmic protein that transfers phosphatidylino-
sitol and phosphatidylcholine between cellular membranes. The
mood-stabilizing drug lithium has been shown to down regulate
PITPNC1 mRNA expression levels in the mouse brain [67].
The top-SNP in the major depression male material is placed
downstream of the gene growth factor receptor binding protein 14
(GRB14), which is a protein that performs both adaptor and
modulatory roles in receptor tyrosine kinase signaling.
It has been shown that the estrogen receptor DNA-binding is
distributed within and between genes rather than being restricted
to promoter-proximal regions. Only a small portion (5%) of ER
binding sites are within 5 kb of the transcriptional start site of a
gene. The majority (38%) of the binding places are instead located
intragenic to the introns of genes whereas functional ER-binding
sites are rarely seen in the exons. Furthermore, the ER binding is
not limited by binding site orientation and about equal amount of
binding occurs within 100 kb from the 59 start site (23%) as within
100 kb of the 39 polyadenylation site (19%) [29,30].
All of the identified SNPs, except rs6517590, are placed either
within or close to genes that previously have been shown to be
regulated by estrogen (see Table 3). The effect on the gene and/or
protein expression varies from inhibiting, as for TGM2 and
GRB14, to enhancing, as for PITPNC1, or both, as for PRKCE,
where the effect depends on the stimulation context within the cell
[33–35,68–71].
One limitation of our study is that ER-binding data is derived
from one single cell-line type and that relevance of the identified
binding sites elsewhere remains to be established. Furthermore,
functional studies need to be carried out to confirm influence of
polymorphism on ER-activity. Finally, as always in complex
genetics, our results need to be replicated in other materials before
final judgment.
In conclusion, we performed the first study on ER-DNA
binding variation in mood disorders. Due to previously reported
differences in the prevalence and etiology of mood disorders
between women and men, we studied each gender separately. Our
results suggest that there is a gender difference in the genetic
pattern contributing to the susceptibility of developing these
disorders and that differences in estrogen receptor binding might
contribute to a risk of developing bipolar disorder in women.
ER DNA-Binding Variation in Mood Disorders
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e32304After correcting for multiple testing, a significant association was
found for rs6023059, placed in the downstream genomic region of
TGM2, in women with bipolar disorder. Thus, fluctuating levels of
estrogen as a triggering factor in combination with specific variants
in this estrogen interacting gene may be involved in the disease
etiology of bipolar disorder in women.
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